Regencell Bioscience Holdings Ltd (RGC) SEC Filings & Earnings Calls
EquiReason read 10 Regencell Bioscience Holdings Ltd SEC filings in the last 12 months. Latest: 20-F on 2026-10-07 — Annual net loss widened to $11.70M from $3.58M, driven by higher G&A and R&D expenses..
Source: SEC EDGAR filings · read by EquiReason
- Market cap
- 3.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
7 Oct 202620-FAnnual net loss widened to $11.70M from $3.58M, driven by higher G&A and R&D expenses.earningsopen
Figures in the filing · each found in the filing text
| Net losses · FY2026 | $-12M | +226% y/y |
| General and administrative expenses · FY2026 | $10M | +270% y/y |
| Research and development expenses · FY2026 | $1M | +37% y/y |
| Cash and cash equivalents · 2026-06-30 | $14M | |
| Share-based compensation expense · FY2026 | $3M | +1246% y/y |
| Net cash used in operating activities · FY2026 | $-8M | +147% y/y |
| Net proceeds from registered direct offering · 2026-05-22 | $19M | |
| Selling and marketing expenses · FY2026 | $6486.00 | -19% y/y |
Risks flagged
Material weaknesses in internal controls
“we identified three material weaknesses in our internal control over financial reporting”
Extreme share price volatility
“Over the course of 2025, the closing price of our Ordinary Shares on the Nasdaq Stock Market LLC ranged from as low as $0.093 per share to as high as $78.000 per share.” · word for word
DOJ investigation
“significant legal and professional fees in connection with the ongoing DOJ investigation into trading of our Ordinary Shares” · word for word
PFIC status
“we believe we were a PFIC for such taxable year due to the amount of interest income we received relative to other income” · word for word
No revenue or approved products
“We have not generated any revenue from the sale of any products for the years ended June 30, 2026 and 2025, respectively.” · word for word
22 May 20266-KRegencell Bioscience announces closing of $20M registered direct offering of 985,222 ordinary shares at $20.30 per share, led by a new institutional investor.open
Figures in the filing · each found in the filing text
| Gross proceeds · 2026-05-22 | $20M | |
| Shares sold · 2026-05-22 | 985,222 | |
| Price per share · 2026-05-22 | $20.30 |
Risks flagged
Dilution from equity offering.
“Issuance of 985,222 ordinary shares.”
Early-stage company with no approved products; high business risk.
“Company is an early-stage bioscience company focusing on Traditional Chinese Medicine.”
19 May 20266-KRegencell Bioscience announces registered direct offering of 985,222 ordinary shares at $20.30 per share for expected gross proceeds of $20M, led by a new institutional investor.open
Figures in the filing · each found in the filing text
| Expected gross proceeds · 2026-05-19 | $20M | |
| Shares offered · 2026-05-19 | 985,222 | |
| Price per share · 2026-05-19 | $20.30 |
Risks flagged
Dilution from equity offering.
“Issuance of 985,222 ordinary shares.”
Early-stage company with no approved products; high business risk.
“Company is an early-stage bioscience company focusing on Traditional Chinese Medicine.”
19 May 20266-KRegencell Bioscience announces registered direct offering of 985,222 ordinary shares at $20.30 per share for ~$20M gross proceeds, led by a new institutional investor.open
Figures in the filing · each found in the filing text
| Gross proceeds · May 2026 | $20M | |
| Shares offered · May 2026 | 985,222 | |
| Offering price per share · May 2026 | $20.30 |
Risks flagged
Dilution risk from new share issuance; early-stage company with no revenue and high cash burn.
“985,222 new shares issued; net loss of $5.3M in H1 2026; accumulated deficit $30.5M”
8 May 20266-KRegencell Bioscience reports H1 2026 net loss of $5.3M vs $1.9M loss in prior year; cash burn continues; no revenue; accumulated deficit grows to $30.5M.earningsopen
Figures in the filing · each found in the filing text
| Net loss · H1 2026 | $5M | +187% y/y |
| Cash · Dec 31, 2025 | $2M | |
| Total assets · Dec 31, 2025 | $3M | |
| Accumulated deficit · Dec 31, 2025 | $31M | |
| Operating expenses · H1 2026 | $5M | +170% y/y |
| General and administrative · H1 2026 | $5M | +236% y/y |
| Research and development · H1 2026 | $416030.00 | -18% y/y |
| Loss per share · H1 2026 | $1.08 | +192% y/y |
| Cash used in operating activities · H1 2026 | $3M | +52% y/y |
Risks flagged
Pre-revenue bioscience company with widening losses, high cash burn, and no near-term revenue visibility.
“Net loss $5.3M vs $1.9M; cash burn $2.6M in H1 2026; accumulated deficit $30.5M; cash $2.36M”
17 Apr 20266-KRegencell Bioscience Holdings Limited announced the dismissal of Marcum Asia CPAs LLP and appointment of HTL International, LLC as its independent registered public accounting firm, effective April 16, 2026. No disagreements or reportable eopen
Risks flagged
Going concern qualification in prior audit reports indicates financial uncertainty.
“Marcum Asia's audit report included an explanatory paragraph related to the Company's ability to continue as a going concern.”
30 Mar 20266-KRegencell Bioscience Holdings Limited filed a sales agreement with Univest Securities, LLC for an at-the-market offering of ordinary shares, potentially up to $500 million, indicating potential dilution.open
Risks flagged
Potential dilution from ATM offering of up to $500M.
“Up to $500,000,000 of ordinary shares may be offered and sold.”
30 Mar 20266-KRegencell Bioscience Holdings Limited announced an at-the-market offering of up to $500 million of ordinary shares, with proceeds for working capital and general corporate purposes.open
Risks flagged
Potential dilution from ATM offering of up to $500M.
“Up to $500,000,000 of ordinary shares may be offered and sold.”
31 Oct 202520-FAnnual report for FY2025 showing continued net loss of $3.58M, no revenue, and going concern doubt.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · FY2025 | $4M | -18% y/y |
| Cash and Cash Equivalents · FY2025 | $2M | -18% y/y |
| Accumulated Deficit · FY2025 | $25M | |
| Research and Development Expenses · FY2025 | $948289.00 | -11% y/y |
| General and Administrative Expenses · FY2025 | $3M | -21% y/y |
| Selling and Marketing Expenses · FY2025 | $8014.00 | -94% y/y |
| Net Cash Used in Operating Activities · FY2025 | $3M | -22% y/y |
| Net Cash Provided by Investing Activities · FY2025 | $3M | -49% y/y |
| Share-Based Compensation Expense · FY2025 | $240000.00 | -47% y/y |
Risks flagged
Going Concern Uncertainty
“In the audit report issued in connection with our financial statements as of and for the year ended June 30, 2025, our independent registered public accounting firm included a going concern explanatory paragraph which stated there was substantial doubt about our ability to continue as a going concern.” · word for word
No Revenue or Approved Products
“We have no saleable products and have not generated any revenue from product sales.” · word for word
Material Weaknesses in Internal Controls
“we and our independent registered public accounting firms identified three material weaknesses in our internal control over financial reporting” · word for word
Concentrated Control by CEO
“Mr. Yat-Gai Au, our founder, director and CEO, currently beneficially owns 88.6% of our company through Regencell (BVI) Limited and his spouse” · word for word
PFIC Status
“Based on the composition of our income and assets for our taxable year ended June 30, 2025, we believe we were a PFIC for such taxable year” · word for word
Regencell Bioscience Holdings Ltd — questions
- What did Regencell Bioscience Holdings Ltd file recently?
- 10 SEC filings in the last 12 months. Latest: 20-F on 2026-10-07 — Annual net loss widened to $11.70M from $3.58M, driven by higher G&A and R&D expenses.
Every figure on this page comes from Regencell Bioscience Holdings Ltd's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.